Efficacy and safety of the extract of Serenoa repens in the treatment of benign prostatic hyperplasia: Therapeutic equivalence between twice and once daily dosage forms

Phytotherapy Research

Volumn 11, Issue 8, 1997, Pages 558-563

  Braeckman, J ^a   Bruhwyler, J ^b   Vandekerckhove, K ^b   Geczy J ^b  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^b Therabel Pharma Belgium   (Belgium)

Author keywords

Benign prostatic hyperplasia (BPH); Extract of Serenoa repens; Once daily dosage form; Phytotherapy

Indexed keywords

ARTICLE; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; EVOLUTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSTATE HYPERTROPHY; PROSTATECTOMY; QUALITY OF LIFE; SABAL; TRANSURETHRAL RESECTION;

SABAL; SERENOA REPENS;

EID: 0031453234     PISSN: 0951418X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1573(199712)11:8<558::AID-PTR158>3.0.CO;2-U     Document Type: Article

References (21)

1. Braeckman, J. (1994). The extract of Serenoa repens in the treatment of benign prostatic hyperplasia: a multicenter open study. Curr. Ther. Res. 55, 776-785.
2. Braeckman, J., Bruhwyler, J., Brichard, B., and Géczy, J. (1997). Efficacy and safety of the extract of Serenoa repens in the treatment of benign prostatic hyperplasia: an open multicentre study. Eur. J. Clin. Res. 9, 1-11.
3. Braeckman, J., Denis, L., de Leval, J. et al. (in press). A double-blind, placebo-controlled study of the plant extract Serenoa repens in the treatment of benign hyperplasia of the prostate. Eur. J. Clin. Res.
4. Breu, W., Hagenlocher, M., Redl, K., Tittel, G., Stadler, F., and Wagner, H. (1992). Antiphlogistische Wirkung eines mit hyperkritischem Kohlendioxid gewonnenen Sabalfrucht-Extraktes. Arzneimittelforsch./Drug Res. 42, 547-551.
5. Bruhwyler, J. (1994). Prostaserene. Purified extract of Serenoa repens. Treatment for BPH. Drugs of the Future 19, 452-453.
6. Carraro, J. C., Raynaud, J. P., Koch, G. et al. (1996). Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1098 patients. The Prostate 29, 231-240.
7. Champault, G., Patel, J. C., and Bonnard, A. M. (1984). A double-blind trial of an extract of the plant Serenoa repens in benign prostatic hyperplasia. Br. J. Clin. Pharmacol. 18, 461-462.
8. Cukier, P. R., Ducassou, P., and Le Guillou, P. (1985). Permixon versus placebo. Résultats d'une étude multicentrique. Comptes Rendus de Thérapeutique et de Pharmacologie Clinique 4, 15-21.
9. Denis, L. J. (1993). Quantification and incidence of benign prostatic hyperplasia. Drugs of Today 29, 328-333.
10. Di Silverio, F., D'Eramo, G., Lubrano, C. et al. (1992). Evidence that Serenoa repens extract displays an antiestrogenic activity in prostatic tissue of benign prostatic hypertrophy patients. Eur. Urol. 21, 309-314.
11. Gutiérrez, M., Hidalgo, A., and Cantabrana, B. (1996). Spasmolytic activity of a lipidic extract from Sabal serrulata fruits: further study of the mechanisms underlying this activity. Planta Med. 62, 507-511.
12. Lepor, H., and Rigaud, G. (1990). The efficacy of transurethral resection of the prostate in men with moderate symptoms of prostatism. J. Urol. 143, 533-537.
13. Lowe, F. C., and Ku, J. C. (1996). Phytotherapy in treatment of benign prostatic hyperplasia: a critical review. Urology 48, 12-20.
14. Mebust, W. K., Holtgrewe, H. L., Cockett, A. T. K.., Peters, P. C. and the Writing Committee (1989). Transurethral prostatectomy: Immediate and post operative complications. A cooperative study of 13 participating institutions evaluating 3885 patients. J. Urol. 141, 243-247.
15. Odenthal, K. P. (1996). Phytotherapy of benign prostatic hyperplasia (BPH) with Cucurbita, Hypoxis, Pygeum, Urtica and Sabal serrulate (Serenoa repens). Phytother. Res. 10, S141-S143.
16. Otto, U., Wagner, B., and Becker, H. (1992). Transplantation of human benign hyperplastic prostate tissue into nude mice: first results of systemic therapy. Urol. Int. 48, 167-170.
17. Romics, I., Schmitz, H., and Frang, D. (1993). Experience in treating benign prostatic hypertrophy with Sabal serrulate for one year. Int. Urol. Nephrol. 25, 565-569.
18. Rotkin, I. D. (1975). Epidemiology of benign prostatic hypertrophy: review and speculations. In, Benign Prostatic Hyperplasia ed. by T. Grayhack, D. Wilson and M. Sherkenske, pp. 105-116. DHEW Publication No. NIH 76-1113, NIH, New York.
19. Tarayre, J. P., Delhon, A., Lauressergues, H., and Stenger, A. (1983). Action anti-oedémateuse d'un extrait hexanique de drupes de Serenoa repens. Ann. Pharm. Fr. 41, 559-570.
20. Walsh, P. C. (1979). Benign prostatic hyperplasia. In, Campbell's Urology. 4th edn, ed. by J. H. Harrison et al., pp. 949-966. W. B. Saunders, Philadelphia.
21. Weisser, H., Tunn, S., Behnke, B., and Krieg, M. (1996). Effects of the Sabal serrulata extract IDS 89 and its subfractions on 5 alpha-reductase activity in human benign prostatic hyperplasia. The Prostate 28, 300-306.